Synthetic procedures for the preparation of 8-ethynylxanthines by treating 8-bromocaffeine and 8-bromopentoxifylline with terminal acetylenes were elaborated. Certain ethynylxanthine derivatives exhibit high in vitro antiproliferative activity against a panel of cancer cell lines, matrix metalloproteinase and in vitro angiogenesis inhibitory activity. Ca2+ channel blocking and agonist activity of the synthesized ethynylxanthines was discussed based on data obtained on the H9C2, SH-SY5Y, and A7R5 cell lines.
Similar content being viewed by others
References
Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Ca–Cancer J. Clin. 2011, 61, 69.
Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Ca–Cancer J. Clin. 2010, 60, 277.
Siegel, R. L.; Miller, K. D.; Jemal, A. Ca–Cancer J. Clin. 2017, 67, 7.
Siegal, T. J. Neuro-Oncology 2013, 15, 656.
Lampson, L. A. Drug Discovery Today 2009, 14, 185.
Huse, J. T.; Holland, E. C. Nat. Rev. Cancer 2010, 10, 319.
Wilson, K. M.; Kasperzyk, J. L.; Rider, J. R.; Kenfield, S.; van Dam, R. M.; Stampfer, M. J.; Giovannucci, E.; Mucci, L. A. J. Nat. Cancer Inst. 2010, 103, 876.
Geybels, M. S.; Neuhouser, M. L.; Wright, J. L.; Stott-Miller, M.; Stanford, J. L. Cancer, Causes Control 2013, 24, 1947.
Bravi, F.; Bosetti, C.; Tavani, A.; Bagnardi, V.; Gallus, S.; Negri, E.; Franceschi, S.; La Vecchia, C. Hepatology 2007, 46, 430.
Yamamoto, N.; Tsuchiya, H. J. Caffeine Res. 2011, 1, 163.
Hayashi, M.; Tsuchiya, H.; Yamamoto, N.; Karita, M.; Shirai, T.; Nishida, H.; Takeuchi, A.; Tomita, K. Anticancer Res. 2005, 25, 2399.
Ding, R.; Shi, J.; Pabon, K.; Scotto, K. W. Mol. Pharmacol. 2012, 81, 328.
Vartanyan, L. P.; Kolesova, M. B.; Gornaeva, G. F.; Pustovalov, Yu. I. Psychopharmacol. Biol. Narcol. [In Russian] 2005, 5, 1093.
Rybár, A.; Pfleiderer, W. Collect. Czeh. Chem. Commun. 1987, 52, 2730.
Soltani Rad, M. N.; Behrouz, S.; Nekoei, A.-R. Synlett 2012, 1191.
Arsenyan, P.; Rubina, K.; Vasiljeva, J.; Belyakov, S. Tetrahedron Lett. 2013, 54, 6524.
Schafer, B.; Gschwind, A.; Ullrich, A. Oncogene 2004, 23, 991.
Yamazaki, D.; Kurisu, S.; Takenawa, T. Cancer Sci. 2005, 96, 379.
Ridley, A. J.; Schwartz, M. A.; Burridge, K.; Firtel, R. A.; Ginsberg, M. H.; Borisy, G.; Parsons, J. T.; Horwitz, A. R. Science 2003, 302, 1704.
Berridge, M. J.; Bootman, M. D.; Lipp, P. Nature 1998, 395, 645.
Rousseau, E.; Ladine, J.; Liu, Q.-Y.; Meissner, G. Arch. Biochem. Biophys. 1988, 267, 75.
Garavito-Aguilar, Z. V.; Recio-Pinto, E.; Corrales, A. V.; Zhang, J.; Blanck, T. J. J.; Xu, F. Brain Res. 2004, 1011, 177.
Rucins, M.; Gosteva, M.; Domracheva, I.; Kanepe-Lapsa, I.; Belyakov, S.; Plotniece, M.; Pajuste, K.; Cekavicus, B.; Jekabsone, M.; Sobolev, A.; Shestakova, I.; Plotniece, А. Chem. Heterocycl. Compd. 2015, 50, 1432. [Khim. Geterotsikl. Soedin. 2014, 1557.]
Berridge, M. J. Neuron 1998, 21, 13.
Verkhratsky, A. Physiol. Rev. 2005, 85, 201.
Fleischer, S.; Inui, M. Prog. Clin. Biol. Res. 1988, 273, 435.
Thomas, N. L.; Williams, A. J. Wiley Interdiscip. Rev.: Membr. Transp. Signaling2012, 1, 383.
Arsenyan, P.; Vasiljeva, J.; Ivanova, A.; Belyakov, S. Mendeleev Commun. 2019, 29, 96.
Schwarz Pharma AG. EP Patent EP1939197 A1, 2008.
Mosmann, T. J. Immunol. Methods 1983, 65, 55.
Ponce, M. L. In Angiogenesis Protocols; Murray, J. C., Ed.; Humana Press, 2001, p. 205.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Arsenyan, P., Vasiljeva, J., Domracheva, I. et al. 8-Ethynylxanthines as promising antiproliferative agents, angiogenesis inhibitors, and calcium channel activity modulators. Chem Heterocycl Comp 56, 776–785 (2020). https://doi.org/10.1007/s10593-020-02730-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10593-020-02730-4